[1]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424-427.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
 LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(4):424-427.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
点击复制

肺动脉高压对扩张型心肌病预后的影响()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年4期
页码:
424-427
栏目:
论著
出版日期:
2020-04-25

文章信息/Info

Title:
The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy
作者:
刘超1 曲杰 1 王明娟 2 徐倩 2 范彦芳 2 周晓慧 2 单伟超 1
(1.承德医学院附属医院,河北 承德 067000;2.承德医学院,河北 承德 067000)
Author(s):
LIU Chao1QU Jie1WANG Mingjuan2XU Qian2FAN Yanfang2ZHOU Xiaohui2SAN Weichao1
(1.Affiliated Hospital of Chengde Medical University,Chengde 067000,Hebei,Chinal; 2.Chengde Medical University,Chengde 067000,Hebei,China)
关键词:
肺动脉高压扩张型心肌病随访预后
Keywords:
Pulmonary hypertension Dilated cardiomyopathy Follow-up Outcomes
DOI:
10.16806/j.cnki.issn.1004-3934.2020.04.023
摘要:
目的 探讨肺动脉高压对扩张型心肌病患者的预后影响。 方法 连续入院2016年1月至2018年12月在本院住院的扩张型心肌病患者。肺动脉高压定义为最大三尖瓣反流速度大于3.0 m/s。随访患者主要终点包括全因死亡、ICD治疗和因心力衰竭住院。结果 共入选139例扩张型心肌病患者,基线平均左室射血分数为31%±5%,其中43.88%的患者合并肺动脉高压。中位随访15个月(1~33个月)期间,33.09% 患者发生主要心血管不良事件。合并PH患者发生主要心血管不良事件风险显著增高(HR 2.202 ,95% CI 1.151 ~4.213,P<0.01)。结论 在扩张型心肌病患者中,合并肺动脉高压的预后差。
Abstract:
Objective To evaluated the long-term prognostic impact of pulmonary hypertension(PH) on dilated cardiomyopathy(DCM) patients. Methods We included all consecutive patients with DCM who had a baseline and follow-up echocardiographic examinations from January 2016 to December 2018. PH was defined as maximal velocity of tricuspid regurgitation(TR Vmax) greater than 3.0 m/s. Primary outcome was major adverse cardiovascular events(MACE),including all-cause mortality, appropriate ICD therapy and admission for heart failure. Results A total of 139 patients with dilated cardiomyopathy were selected, with an average baseline left ventricular blood score of 31%±5%, of which 43.88% combined pulmonary hypertension. During the median follow-up of 15(1~33) months,33.09% of the patient suffered MACE. The risk of MACE in patients with combined PH increased significantly (HR 2.202,95% CI 1.151~4.213,P<0.01). Conclusion The long-term outcome was worse when DCM patients combined PH.

参考文献/References:


[1] Rosenkranz S,Gibbs JS,Wachter R,et al. Left ventricular heart failure and pulmonary hypertension[J]. Eur Heart J,2016,37(12):942-954.

[2] Nakanishi N. 109th Scientific Meeting of the Japanese Society of Internal Medicine:Educational lecture:6.Pulmonary hypertension:the updated clinical classification and the progress in treatment[J]. Nihon Naika Gakkai Zasshi,2012,101(9):2674-2680.

[3] 张艺韬,曾伟杰,程康林. 左心疾病相关肺动脉高压流行病学[J]. 心血管病学进展,2016,37(4):333-336.

[4] Galie N,Humbert M,Vachiery JL,et al. 2015 esc/ers guidelines for the diagnosis and treatment of pulmonary hypertension:The Joint Task Force For The Diagnosis and Treatment of Pulmonary Hypertension of the european Society of Cardiology(ESC) and the European Respiratory Society(ERS):Endorsed by:Association for European Paediatric and Congenital Cardiology(AEPC),International Society for Heart and Lung Transplantation(ISHLT)[J]. Eur Heart J,2016,37(1):67-119.

[5] Chung K,Strange G,Codde J,et al. Left heart disease and pulmonary hypertension:Are we seeing the full picture?[J]. Heart Lung Circ,2018,27(3):301-309.

[6] Richardson P,McKenna W,Bristow M,et al. Report of the 1995 world health organization/international society and federation of cardiology task force on the definition and classification of cardiomyopathies[J]. Circulation,1996,93(5):841-842.

[7] Kwon HJ,Park JH,Park JJ,et al. Improvement of left ventricular ejection fraction and pulmonary hypertension are significant prognostic factors in heart failure with reduced ejection fraction patients[J]. J Cardiovasc Imaging,2019,27(4):257-265.

[8] 王世鹏,徐俊波,胡咏梅等. 扩张型心肌病研究进展[J]. 心血管病学进展,2017,38(2):229-232.

[9] Kalogeropoulos AP,Georgiopoulou VV,Borlaug BA,et al. Left ventricular dysfunction with pulmonary hypertension:Part 2:Prognosis,noninvasive evaluation,treatment,and future research[J]. Circ Heart Fail,2013,6(3):584-593.

[10] 田晶,张青,张岩波,等. 慢性心力衰竭结局评价指标研究进展[J]. 心血管病学进展,2019,40(6):931-935.

[11] Georgiopoulou VV,Kalogeropoulos AP,Borlaug BA,et al. Left ventricular dysfunction with pulmonary hypertension:Part 1:Epidemiology,pathophysiology,and definitions[J]. Circ Heart Fail,2013,6(2):344-354.

[12] Merlos P,Nú?ez J,Sanchis J,et al. Echocardiographic estimation of pulmonary arterial systolic pressure in acute heart failure. Prognostic implications[J]. Eur J Intern Med,2013,24(6):562-567.

[13] Santas E,de la Espriella-Juan R,Mollar A,et al. Echocardiographic pulmonary artery pressure estimation and heart failure rehospitalization burden in patients with acute heart failure[J]. Int J Cardiol,2017,241:407-410.

[14] Santas E,Chorro FJ,Minana G,et al. Tricuspid regurgitation and mortality risk across left ventricular systolic function in acute heart failure[J]. Circ J,2015,79(7):1526-1533.

相似文献/References:

[1]张颖雪,赵新湘,孙勇.心脏磁共振成像技术在扩张型心肌病中的应用及研究进展[J].心血管病学进展,2016,(1):74.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.019]
 ZHANG Yingxue,ZHAO Xinxiang,SUN Yong.Application and Research Progress of Cardiac Magnetic Resonance Imaging in Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(4):74.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.019]
[2]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
 MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(4):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[3]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
 ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[4]吴琼,杨爱玲,周端,等.扩张型心肌病左室逆重构的研究进展[J].心血管病学进展,2019,(6):885.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.012]
 WU Qiong,YANG Ailing,ZHOU Duan,et al.Left Ventricular Reverse Remodeling in Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(4):885.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.012]
[5]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
 WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(4):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[6]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
 WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(4):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[7]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
 DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(4):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[8]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
 ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(4):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[9]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
 ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(4):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[10]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
 HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(4):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]

备注/Memo

备注/Memo:
基金项目:河北省卫生计生委医学科学研究重点课题项目(20181153)
通讯作者:单伟超,E-mail:326185092@qq.com
收稿时间:2019-11-20
更新日期/Last Update: 2020-07-29